Company,
About Biomunex
BRINGING FORTH THE NEXT STAGE OF MULTISPECIFIC ANTIBODY THERAPIES
2014
Biomunex creation
in France.
2019
Biomunex’s U.S. subsidiary Creation.
Research Collaboration on MAIT engagers.
1st out-licensing agreement with Sanofi.
2021
2ND Out-licensing and co-development agreement with ONWARD Therapeutics.
2024
Phase 1 clinical trial (BMX-101).
3rd out-licensing agreement with Ipsen.
1st out-licensing agreement with Sanofi.
2026
AI collaborations with Gordion Bioscience and Tangramed Biotech.
At a glance
2014
Biomunex creation
3
European academic institutions co-founding research
2019
MAIT engagers – Institut Curie collaboration
2
HQ locations – Paris & Cambridge, MA
Who we are
BIOMUNEX: DISRUPTIVE INNOVATION IN ONCOLOGY
Biomunex Pharmaceuticals is a Paris- and Cambridge-based biopharmaceutical company specializing in the discovery and development of innovative therapeutic approaches based on solid data and biological and clinical evidence to address unmet medical needs in oncology.
Founded by Dr. Pierre-Emmanuel Gerard in 2014, the company focuses on disruptive biological strategies to deliver breakthrough treatments to cancer patients. At the heart of this mission: the proprietary BiXAb® platform technologies.
Founding research
The original patent was based on a pioneering multi-specific antibody research work between different European universities (from Switzerland, France, Italy), that led to a unique next generation format, out licensed to Biomunex in 2015.
BiXAb® plateform technologies
The Biomunex team built BiXAb® platform technologies, i.e., best-in-class bispecific and multi-specific antibody technologies, backed by a robust intellectual property portfolio granted worldwide, enabling rapid generation of antibodies from any pair of monoclonals as building blocks, in a straightforward, fast and cost-effective fashion.
MAIT engagers
Together with Institut Curie (Paris, France), the Biomunex team co-invented the unique MAIT engager approach, a disruptive T-cell engager technology, combining cutting-edge antibody engineering with Curie’s discovery of MAIT cells to pioneer a breakthrough immunotherapy approach based on MAIT cell engagement.
MAIT ENGAGERS : A breakthrough approach beyond classical classical CD3 T-cell engagers
Potency comparable to classical CD3+ TCEs — with a potential significantly improved safety profile
Wider therapeutic window in specific solid tumor types by reducing limitations of current CD3+ T-cell engager therapies, including activation of regulatory T-cells and cytokine release syndrome
Triggers the “SPARK effect”: direct cytotoxicity + induced secondary immune response for durable anti-cancer reponse
Highly differentiated pipeline of MAIT engager drug candidates vs. classical TCE approaches
Our technology
The BiXAb® platforms : best-in-class profile
The BiXAb® platform technologies combine speed, drug-like properties, and multi-specific capability — setting a new standard for bispecific and multi-specific antibody development in immuno-oncology.
Process rapidity
4 weeks from in silico design to the characterization of an original antibody and its modularity.
Excellent drug-like properties
Excellent pairing, no steric hindrance,
Excellent solubility, thermal stability,
low immunogenicity thanks to human origin linkers,
Excellent biomanufacturing, leading to high yield and cost-effective manufacturing.
Multi-specific capability and versatility
Tetravalent or bivalent targeting, tri-specificity, multi-specificity, bispecific ADCs — many modes of action.
Biomunex’s most advanced BiXAb® candidates have demonstrated compelling efficacy — in vitro, in vivo, ex vivo, and in organoid models — across both solid tumors or hematological malignancies. Preclinical and clinical developments are ongoing across multiple disruptive bispecific antibody programs.